Boston Common Asset Management LLC Decreases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Boston Common Asset Management LLC reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 26.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 152,532 shares of the medical research company’s stock after selling 55,392 shares during the period. Boston Common Asset Management LLC’s holdings in Edwards Lifesciences were worth $11,292,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EW. JFS Wealth Advisors LLC raised its position in Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares during the last quarter. Seascape Capital Management raised its position in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after purchasing an additional 174 shares during the last quarter. Cooper Financial Group lifted its stake in Edwards Lifesciences by 2.8% in the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after buying an additional 175 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. grew its holdings in Edwards Lifesciences by 1.2% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company’s stock valued at $1,417,000 after buying an additional 184 shares during the last quarter. Finally, Martin Capital Advisors LLP increased its position in Edwards Lifesciences by 0.7% during the third quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock worth $1,686,000 after buying an additional 186 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on EW shares. Royal Bank of Canada upped their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, December 5th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Wolfe Research downgraded shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target for the company. in a report on Thursday. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Finally, Robert W. Baird lowered their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $78.48.

Edwards Lifesciences Stock Up 0.4 %

Shares of NYSE EW traded up $0.26 on Friday, hitting $70.12. The company had a trading volume of 612,582 shares, compared to its average volume of 3,824,776. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a market capitalization of $41.35 billion, a P/E ratio of 10.11, a PEG ratio of 3.77 and a beta of 1.11. The business has a 50 day moving average of $71.91 and a two-hundred day moving average of $71.61.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.59 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 33,000 shares of company stock valued at $2,195,180. Corporate insiders own 1.27% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.